OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial

Burosumab, a fully human IgG1 monoclonal antibody to FGF23, is approved in Canada and Brazil to treat XLH in patients ≥1 year of age and in the US to treat XLH in patients ≥6 months of age. Burosumab has also received conditional marketing authorization in Europe to treat XLH with radiographic evide...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Endocr Soc
Egile Nagusiak: Perwad, Farzana, Portale, Anthony A, Carpenter, Thomas O, Briot, Karine, Imel, Erik Allen, Kamenicky, Peter, Weber, Thomas Joseph, Pitukcheewanont, Pisit, Cheong, Hae Il, De Beur, Suzanne Marie Jan, Imanishi, Yasuo, Ito, Nobuaki, Lachmann, Robin, Tanaka, Hiroyuki, Zhang, Lin, Skrinar, Alison, Rees, Linda, Insogna, Karl Leonard
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Bone and Mineral Metabolism
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209551/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.147
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak